During the past decade, Onkologische Schwerpunktpraxis Eppendorf conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 1 clinical trials were completed, i.e. on average, 11.1% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 1 clinical trials were completed. i.e. 25% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Onkologische Schwerpunktpraxis Eppendorf" #1 sponsor was "iOMEDICO AG" with 2 trials, followed by "BeiGene" with 1 trials sponsored, "EMD Serono Research & Development Institute, Inc." with 1 trials sponsored, "Ganymed Pharmaceuticals GmbH" with 1 trials sponsored and "Gilead Sciences" with 1 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Onkologische Schwerpunktpraxis Eppendorf" #1 collaborator was "Roche Pharma AG" with 2 trials as a collaborator, "Arbeitsgemeinschaft fur Internistische Onkologie" with 1 trials as a collaborator, "Arbeitskreis Klinische Studien" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator and "Clinical Trial Center North (CTC North GmbH & Co. KG)" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Onkologische Schwerpunktpraxis Eppendorf" are "Metastatic Breast Cancer" (2 trials), "Adenocarcinoma of the Esophagogastric Junction" (1 trials), "Advanced Gastric or EGJ Cancer" (1 trials), "Advanced Solid Tumors or Hematologic Malignancies" (1 trials) and "Advanced or Metastatic Cholangiocellular Carcinoma and Bile Duct" (1 trials). Many other conditions were trialed in "Onkologische Schwerpunktpraxis Eppendorf" in a lesser frequency.

Most popular intervention types in "Onkologische Schwerpunktpraxis Eppendorf" are "Drug" (10 trials), "Other" (2 trials), "Biological" (1 trials), "Combination Product" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Capecitabine" (3 trials), "Oxaliplatin" (3 trials), "Atezolizumab" (2 trials), "Docetaxel" (2 trials) and "Gemcitabine" (2 trials). Other intervention names were less common.

The vast majority of trials in "Onkologische Schwerpunktpraxis Eppendorf" are 12 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Onkologische Schwerpunktpraxis Eppendorf". undefined are not yet recruiting, 3 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Onkologische Schwerpunktpraxis Eppendorf, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Onkologische Schwerpunktpraxis Eppendorf, 1 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".